NO20004881L - Pyrrolo [1,2-a] pyrazine sPLA2 inhibitor - Google Patents

Pyrrolo [1,2-a] pyrazine sPLA2 inhibitor

Info

Publication number
NO20004881L
NO20004881L NO20004881A NO20004881A NO20004881L NO 20004881 L NO20004881 L NO 20004881L NO 20004881 A NO20004881 A NO 20004881A NO 20004881 A NO20004881 A NO 20004881A NO 20004881 L NO20004881 L NO 20004881L
Authority
NO
Norway
Prior art keywords
pyrrolo
pyrazine
atoms
similar
group
Prior art date
Application number
NO20004881A
Other languages
Norwegian (no)
Other versions
NO20004881D0 (en
Inventor
Mitsuaki Ohtani
Masahiro Fuji
Tetsuo Okada
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO20004881D0 publication Critical patent/NO20004881D0/en
Publication of NO20004881L publication Critical patent/NO20004881L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Formel (I), hvori Rer -(L)-Rhvorier en toverdig bindingsgruppe med 1 til 18 atomer eller lignende, oger en karbocyklisk ring substituert med minst en ikke-interfererende substituent eller lignende, Rer Cl til C3 alkyl, C3 til C4 cykloalkyl eller en lignende gruppe, Rer -(L2) -. (sur gruppe), Rog Rhydrogenatomer, ikke-interfererende substituenter, karbocykliske grupper eller lignende, "RA er. -C(=)-(=)-eller lignende, og X er uavhengig oksygen-atom eller svovelatom, prodrugs derav, deres farmasøytisk akseptable salter, eller deres solvater og et preparat for inhibering av sPLAinneholdende disse som effektive bestand-deler .Formula (I), wherein R 1 - (L) -R 1 comprises a divalent linking group having 1 to 18 atoms or the like, or a carbocyclic ring substituted with at least one non-interfering substituent or the like, R a similar group, Rer - (L2) -. (acid group), Rog Rhydrogen atoms, non-interfering substituents, carbocyclic groups or the like, "RA is -C (=) - (=) - or similar, and X is independently oxygen atom or sulfur atom, prodrugs thereof, their pharmaceutical acceptable salts, or their solvates and a preparation for inhibiting sPLA-containing these as effective constituents.

NO20004881A 1998-03-31 2000-09-28 Pyrrolo [1,2-a] pyrazine sPLA2 inhibitor NO20004881L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8599798 1998-03-31
JP24473598 1998-08-31
PCT/JP1999/001670 WO1999051605A1 (en) 1998-03-31 1999-03-31 PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR

Publications (2)

Publication Number Publication Date
NO20004881D0 NO20004881D0 (en) 2000-09-28
NO20004881L true NO20004881L (en) 2000-11-28

Family

ID=26427020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004881A NO20004881L (en) 1998-03-31 2000-09-28 Pyrrolo [1,2-a] pyrazine sPLA2 inhibitor

Country Status (11)

Country Link
US (1) US6407104B1 (en)
EP (1) EP1066290A1 (en)
JP (1) JP4412521B2 (en)
KR (1) KR20010042307A (en)
CN (1) CN1303384A (en)
AU (1) AU3054399A (en)
BR (1) BR9909345A (en)
CA (1) CA2326522A1 (en)
HU (1) HUP0102981A3 (en)
NO (1) NO20004881L (en)
WO (1) WO1999051605A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6004799A (en) * 1998-10-14 2000-05-01 Shionogi & Co., Ltd. Remedies or preventives for ischemic reflow failure
AU6015600A (en) 1999-07-19 2001-02-05 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
JP4623483B2 (en) 1999-08-23 2011-02-02 塩野義製薬株式会社 Pyrrotriazine derivative having sPLA2 inhibitory action
AU7559600A (en) * 1999-10-15 2001-04-23 Shionogi & Co., Ltd. V type and/or x type spla2 inhibitors
AU1304801A (en) 1999-11-15 2001-05-30 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an SPLA2- inhibiting effect
JPWO2002000621A1 (en) * 2000-06-29 2004-04-22 塩野義製薬株式会社 Compound having X-type sPLA2 inhibitory action
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
AUPQ876400A0 (en) * 2000-07-14 2000-08-03 University Of Queensland, The Compositions and method of using them
WO2002012249A2 (en) * 2000-08-04 2002-02-14 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
TWI314457B (en) * 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
DE10155727A1 (en) * 2001-11-13 2003-05-28 Morphochem Ag Serine protease inhibitors
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
ES2431050T3 (en) * 2005-08-04 2013-11-22 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as modulators of sirtuin
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CN105622616A (en) * 2016-02-25 2016-06-01 上海雅本化学有限公司 Preparation method of 4-chloropyrrolo[2,3-d]pyrimidine
EP4378924A4 (en) * 2021-09-17 2025-09-03 Mitsui Chemicals Inc PREPARATION PROCESS FOR (METH)ACRYLAMIDE COMPOUND

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
ES2377223T3 (en) 1994-04-01 2012-03-23 Eli Lilly And Company [[3- (2-Amino-1,2-dioxoethyl) -2-ethyl-1- (phenylmethyl) -11H-indole-4-IL] oxy] acetic acid methyl ester as an inhibitor of sPLA2
EP0772596B1 (en) * 1994-07-21 2003-10-01 Eli Lilly And Company INDOLIZINE sPLA2 INHIBITORS
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
ES2174034T3 (en) 1995-12-13 2002-11-01 Lilly Co Eli NAFTILGLIOXAMIDS AS SPLA2 INHIBITORS
JP2000501739A (en) 1995-12-13 2000-02-15 イーライ・リリー・アンド・カンパニー sPLA (2) Naphthylacetamide as an inhibitor
NZ335246A (en) 1996-10-30 2001-09-28 Lilly Co Eli Substituted carbazole or hydrogenated carbazole derivatives; useful for inhibiting sPLA2 (human non-pancreatic secretory phospholipase A2) mediated release of fatty acids for conditions such as septic shock
US5916922A (en) 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors
US6353128B1 (en) 1996-12-03 2002-03-05 Eli Lilly And Company Phenyl acetamides as sPLA2 inhibitors
ID18983A (en) 1996-12-04 1998-05-28 Lilly Co Eli PIRAZOLA AS AN NON-PANCREAS PHOSPHOLIPASE SECRETARY SECRESSION IN HUMAN
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
TW455581B (en) 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides

Also Published As

Publication number Publication date
HUP0102981A2 (en) 2002-01-28
BR9909345A (en) 2000-12-12
CA2326522A1 (en) 1999-10-14
JP4412521B2 (en) 2010-02-10
NO20004881D0 (en) 2000-09-28
CN1303384A (en) 2001-07-11
WO1999051605A1 (en) 1999-10-14
US6407104B1 (en) 2002-06-18
EP1066290A1 (en) 2001-01-10
AU3054399A (en) 1999-10-25
HUP0102981A3 (en) 2002-10-28
JP2002530268A (en) 2002-09-17
KR20010042307A (en) 2001-05-25

Similar Documents

Publication Publication Date Title
NO20004881L (en) Pyrrolo [1,2-a] pyrazine sPLA2 inhibitor
BR9911048A (en) Pyrrole spla2 inhibitor [1,2-b] pyridazine
EP0989129A4 (en) PYRAZOLOPYRIDYLPYRIDAZINONE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
NO20012570L (en) Substituted benzimidazoles and their use as PARP inhibitors
NZ507564A (en) 4-substituted carbazole or tetrahydrocarbazole derivatives
EP1103552A4 (en) Benzothiepin derivatives, process for the preparation of the same and uses thereof
DK1106612T3 (en) Quinoline derivatives useful for inhibiting farnesyl protein transferase
CA2205757A1 (en) Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
MX9701893A (en) Novel prostaglandin synthase inhibitors.
IL156873A0 (en) Pharmaceutically active piperidine derivatives
AU5702996A (en) Oxygen-containing heterocyclic compounds
DE69521500D1 (en) PHOSPHORIC ACID DERIVATIVES
DK0628550T3 (en) Pyridazine as interleukin-1 beta-converted enzyme inhibitors
DK0918776T3 (en) Total synthesis of antitumor acylfulvenes
HRP20000585B1 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
TW200624541A (en) Flameproof rubber-reinforced styrenic resin composition
DK0746545T3 (en) Nipecotinic acid derivatives as antithrombotic compounds
YU19099A (en) Substituted tricyclics
CA2209422A1 (en) 4-amino-3-acylnaphthyridine derivatives
NO983444L (en) Benzo (c) quinolizine derivatives, their preparation and use as 5 <alfa> reductase inhibitors
NO934227L (en) Pyrrole derivatives, processes for their preparation and therapeutic use
TW262467B (en)
EP0133038A3 (en) Octahydroindolizinepropanoic acid derivatives as enzyme inhibitors
AP2001002314A0 (en) Substituted benzolactam compounds.
ATE223907T1 (en) ARGINNINE ANALOGUE WITH NO-SYNTAX INHIBITORY EFFECT